Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?

References

• Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis.40(4), 562–573 (2005).
   PubMed Web of Science ®Google Scholar
• Chambers HF. Community-associated MRSA – resistance and virulence converge. N. Engl. J. Med.352(14), 1485–1487 (2005).
   PubMed Web of Science ®Google Scholar
• Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob.5, 2 (2006).
   PubMedGoogle Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med.355(7), 666–674 (2006).
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med.144(5), 309–317 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin. Infect. Dis.39(7), 971–979 (2004).
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. The management of infections due to drug-resistant Gram-positive bacteria. Eur. J. Clin. Microbiol. Infect. Dis.24(12), 777–779 (2005).
   PubMed Web of Science ®Google Scholar
• Ziglam HM, Finch RG. Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clin. Microbiol. Infect.7(Suppl. 4), 53–65 (2001).
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococcal infections. N. Engl. J. Med.342(10), 710–721 (2000).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis.42(Suppl. 1), S40–S50 (2006).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis.38(12), 1700–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42(6), 2398–2402 (2004).
   PubMed Web of Science ®Google Scholar
• Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy27(2), 227–249 (2007).
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Quinupristin–dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis.36(4), 473–481 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti Infect. Ther.2(1), 51–59 (2004).
   PubMedGoogle Scholar
• Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin–dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.44(12), 3408–3413 (2000).
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.49(6), 2260–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther.25(3), 980–992 (2003).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis.32(3), 402–412 (2001).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest124(5), 1789–1797 (2003).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet358(9277), 207–208 (2001).
   PubMed Web of Science ®Google Scholar
• Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am. J. Med. Sci.330(2), 102–104 (2005).
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis.41(Suppl. 5), S303–S314 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin–aztreonam. Clin. Infect. Dis.41(Suppl. 5), S341–S353 (2005).
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis.38(7), 994–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis.38(12), 1673–1681 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med.355(7), 653–665 (2006).
   PubMed Web of Science ®Google Scholar